Carcinoma, Neuroendocrine: all 238 studies
Page 1 of 3. Open to participants first (65), then studies with results posted, then the rest; newest registration first within each.
- ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07833839Phase 3
- A Study of Armored CAR T Cells in People With CancerRecruitingNCT07783477Phase 1
- TLN-499 in Combination With Venetoclax in Patients With Relapsed/Refractory Solid TumorsRecruitingNCT07713732Phase 1
- AK112 Combination Therapy as First Line Treatment for Metastatic Digestive System Neuroendocrine CancerNot yet recruitingNCT07712094Phase 2
- Study of CTX-471 in Patients With Neural Cell Adhesion Molecule (NCAM) Positive Neuroendocrine NeoplasmsNot yet recruitingNCT07684170Phase 2
- A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07595913Phase 3
- A Trial for the Treatment of Advanced Large-Cell Neuroendocrine Cancer of the LungNot yet recruitingNCT07561645Phase 2
- Autologous B7-H3 Chimeric Antigen Receptor T Cells in Previously Treated Extensive-Stage Small Cell Lung Cancer With Recurrent or Refractory DiseaseRecruitingNCT07509034Phase 1
- A First-in-human (FIH), Phase 1 Study of ML261, an Autologous Potency Enhanced Anti-DLL3 CAR T Cell Therapy, in Participants With R/R SCLC or Select NECs (SPECTRAL-1)RecruitingNCT07488923Phase 1
- DLL3-Targeted PET/CT in Neuroendocrine CarcinomaRecruitingNCT07458906Not applicable
- TheraSphere Japan Pre-Market StudyRecruitingNCT07377487Not applicable
- Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01)Not yet recruitingNCT07337447Phase 2
- Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid TumorsRecruitingNCT07278479Phase 1/2
- Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin AmericaRecruitingNCT07192991
- A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung CancerRecruitingNCT07174583Phase 1/2
- Sintilimab in Combination With Surufatinib and Temozolomide in the Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07156019Phase 2
- Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsRecruitingNCT07080242Phase 1
- ZG006 and ZG005 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT07038096Phase 1/2
- A Irinotecan Liposome Trial of in Advanced Neuroendocrine CarcinomaNot yet recruitingNCT07014540Phase 4
- A Trial of MHB088C in Advanced Extrapulmonary Neuroendocrine CancerNot yet recruitingNCT06951243Phase 2
- A Study of MT-4561 in Patients With Various Advanced Solid TumorsRecruitingNCT06943521Phase 1/2
- A Study of 177Lu-DTPA-SC16.56 in People With Neuroendocrine Carcinomas of the Lung and ProstateNot yet recruitingNCT06941480Phase 1
- Tarlatamab vs Standard of Care Chemotherapy in Patients With Pre-treated Advanced, Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Carcinomas (NECs)RecruitingNCT06937905Phase 3
- A Phase I Study of HS-20108 in Participants With Advanced Solid TumorsRecruitingNCT06936735Phase 1
- Efficacy and Safety Evaluation of Tarlatamab in Advanced Extrapulmonary Neuroendocrine Carcinoma PatientsRecruitingNCT06893783Phase 2
- SVV-001 With Nivolumab and Ipilimumab in Patients With Poorly Differentiated Neuroendocrine Carcinomas (NEC) or Well-Differentiated High-Grade Neuroendocrine Tumors (NET)RecruitingNCT06889493Phase 1
- Tarlatamab for Advanced Extrapulmonary Small Cell Carcinoma and Neuroendocrine Carcinoma (TAURUS)RecruitingNCT06816394Phase 2
- Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the CervixEnrolling by invitationNCT06810895
- Ivonescimab in the Treatment of Multiple Advanced TumorsRecruitingNCT06683846Phase 2
- Head-to-head Study of 68Ga-MGS5 Versus 68Ga-DOTATATE PET/CT in Patients With Medullary Thyroid CarcinomaRecruitingNCT06520319Phase 1
- Irinotecan Liposomes for the Treatment of Neuroendocrine CarcinomaNot yet recruitingNCT06485739Phase 4
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Neuroendocrine Carcinoma.RecruitingNCT06440057Phase 1/2
- Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC)RecruitingNCT06418087Phase 2
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityRecruitingNCT06406465Phase 2
- FIRST-NEC (GFPC 01-2022) - Combination of Durvalumab With Etoposide and PlatinumRecruitingNCT06393816Phase 2
- SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine CarcinomaRecruitingNCT06384482Phase 1
- Study of ZG005 in Combination With Etoposide and Cisplatin in Participants With Advanced Neuroendocrine Carcinoma.RecruitingNCT06372626Phase 1/2
- Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLCRecruitingNCT06369181
- YOUNg Adults With Gastro-inteSTinal (GI) and nEuroendocrine canceRs.RecruitingNCT06337760
- Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSIRecruitingNCT06333314Phase 2
- A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)RecruitingNCT06330064Phase 1/2
- Dose Escalation Study of ZG006 in Participants With Advanced Small Cell Lung Cancer or Neuroendocrine Carcinoma, Followed by Dose Expansion Study in Participants With Advanced Small Cell Lung CancerRecruitingNCT06283719Phase 1/2
- Clinical Application of the J-PET Scanner PrototypeRecruitingNCT06242119
- Trial of Lu-177 DOTATATE (Lutathera®) in Unlicensed IndicationsNot yet recruitingNCT06121271Phase 2
- Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine CarcinomaRecruitingNCT06102746
- A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical StudyNot yet recruitingNCT06079723
- First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine CarcinomaRecruitingNCT06070740Phase 2
- A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath TumorsRecruitingNCT06041516Phase 1
- Study of ZG006 in Participants With Small Cell Lung Cancer or Neuroendocrine CarcinomaRecruitingNCT05978284Phase 1/2
- A Single-arm, Open-label, Clinical Trial of Surufatinib/Serplulimab/Platinum/Etoposide in Neuroendocrine Carcinoma.RecruitingNCT05747729Phase 1/2
- Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine NeoplasmsEnrolling by invitationNCT05709171Phase 2
- A Study of TY-1091 in Patients With Advanced Solid TumorsRecruitingNCT05675605Phase 1/2
- A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)RecruitingNCT05652686Phase 1/2
- Simultaneous Hyperpolarized [1-13C]Pyruvate and 18F-FDG PET/MRS in Cancer PatientsEnrolling by invitationNCT05396118Phase 2
- Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC)RecruitingNCT05237934
- A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine CarcinomaRecruitingNCT05015621Phase 3
- Atezolizumab Plus Tivozanib in Immunologically Cold Tumor TypesRecruitingNCT05000294Phase 1/2
- Amyloid Proteins From Medullary Thyroid Cancer and Laryngeal AmyloidosisNot yet recruitingNCT04760171
- Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN)RecruitingNCT04464122
- Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown PrimaryRecruitingNCT04325425Phase 2
- Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine CarcinomasRecruitingNCT04268121Phase 2
- A Study of Repotrectinib (TPX-0005) in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 RearrangementsRecruitingNCT03093116Phase 1/2
- The Molecular Screening Study for the Umbrella Trial (SUKSES) in Relapsed Small Cell Lung Cancer Patients [SUKSES-S]RecruitingNCT02688894
- RegisterNET - A Registry for Neuroendocrine Tumors in the USA and WorldwideEnrolling by invitationNCT02270567
- An Active Surveillance Program for Cases of Medullary Thyroid Carcinoma (MTC)Enrolling by invitationNCT01511393
- Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid TumorsTerminatedNCT05126433Phase 2Results posted
- Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate CancerTerminatedNCT04926181Phase 2Results posted
- Testing the Addition of an Anti-cancer Drug, BAY 1895344, to Usual Chemotherapy for Advanced Stage Solid Tumors, With a Specific Focus on Patients With Small Cell Lung Cancer, Poorly Differentiated Neuroendocrine Cancer, and Pancreatic CancerActive, not recruitingNCT04514497Phase 1Results posted
- Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine CarcinomaCompletedNCT04452292Not applicableResults posted
- Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine TumorsActive, not recruitingNCT04079712Phase 2Results posted
- Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic OriginTerminatedNCT03736720Phase 2Results posted
- Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate CancerTerminatedNCT03649841Phase 2Results posted
- Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine TumorsCompletedNCT03290079Phase 2Results posted
- Pembrolizumab for the Treatment of Recurrent High Grade Neuroendocrine CarcinomaTerminatedNCT03190213Phase 2Results posted
- Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine CarcinomasCompletedNCT03136055Phase 2Results posted
- Pembrolizumab in Recurrent or Metastatic Medullary Thyroid CancerCompletedNCT03072160Phase 2Results posted
- FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine CarcinomasTerminatedNCT03042780Phase 2Results posted
- Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid TumorsCompletedNCT03037385Phase 1/2Results posted
- Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)CompletedNCT02955069Phase 2Results posted
- PEN-221 in Somatostatin Receptor 2 Expressing Advanced Cancers Including Neuroendocrine and Small Cell Lung CancersCompletedNCT02936323Phase 1/2Results posted
- Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by SurgeryCompletedNCT02893930Phase 2Results posted
- Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid TumorsTerminatedNCT02709889Phase 1/2Results posted
- Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine CarcinomasActive, not recruitingNCT02595424Phase 2Results posted
- Trial of Topotecan With VX-970 (M6620), an ATR Kinase Inhibitor, in Small Cell Cancers and Extrapulmonary Small Cell CancersCompletedNCT02487095Phase 1/2Results posted
- Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine CancersCompletedNCT02318784Phase 2Results posted
- Study of Mutation-Targeted Therapy With Sunitinib or Everolimus in People With Advanced Low- or Intermediate-Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive SurgeryTerminatedNCT02315625Phase 2Results posted
- Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by SurgeryCompletedNCT02101918Phase 2Results posted
- P:II Above-Label Octreotide-LAR With Insufficiently Controlled Carcinoid SyndromeTerminatedNCT01886287Phase 2Results posted
- QUILT-3.006 for Recurrent Medullary Thyroid CancerCompletedNCT01856920Phase 2Results posted
- Evaluate the Safety and Tolerability of Vandetanib in Japanese Patients With Medullary Thyroid CarcinomaCompletedNCT01661179Phase 1/2Results posted
- Cisplatin and Etoposide With or Without Veliparib in Treating Patients With Extensive Stage Small Cell Lung CancerCompletedNCT01642251Phase 1/2Results posted
- 3-arm Trial to Evaluate Pasireotide LAR/Everolimus Alone/in Combination in Patients With Lung/Thymus NET - LUNA TrialCompletedNCT01563354Phase 2Results posted
- 68Ga-DOTATATE PET Scan in Neuroendocrine CancerCompletedNCT01396382Phase 2Results posted
- Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine CancersCompletedNCT01121939Phase 2Results posted
- Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
- Capecitabine and Temozolomide for Neuroendocrine CancersCompletedNCT00869050Phase 2Results posted
- Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid CancerCompletedNCT00625846Phase 2Results posted
- Avastin (Bevacizumab) and RAD001 (Everolimus) in Advanced Low or Intermediate Grade Neuroendocrine CarcinomaCompletedNCT00607113Phase 2Results posted
- An Initial Study of Lithium in Patients With Medullary Thyroid CancerTerminatedNCT00582712Phase 2Results posted
- Vandetanib to Treat Children and Adolescents With Medullary Thyroid CancerCompletedNCT00514046Phase 1/2Results posted